---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033155"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T12:49:20.066652+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cerus INTERCEPT RBC Phase 3 trial meets primary non-inferiority endpoint

## Summary
- AKI incidence 29.3% (INTERCEPT RBC) vs 28.0% (conventional); non-inferiority margin 14% (p=0.001).
- Related TEAEs within 28 days: 2.5% vs 0.6% (p=0.130); no adverse health effects from RBC antibodies.
- Modular PMA submission to FDA planned H2 2025; final module expected H2 2026 after RedeS trial.
- ReCePI trial enrolled 581 patients at 18 U.S. sites; funded in part by BARDA contract.

## SEC filing metadata
- accession: 0000950170-24-033155
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000095017024033155/0000950170-24-033155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000095017024033155/cers-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033155
- JSON: https://secwatch.observer/filing/0000950170-24-033155.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.